Endonovo Therapeutics, Inc. announced that Randolph M. Johnson, Ph.D. has been appointed by the Company as its Executive Vice President, Clinical Development and Chief Development Officer, effective immediately, to lead its device clinical product development and regulatory clearance. Previously Dr. Johnson was President and Chief Executive Officer of Innov8r Therapeutics. Prior, he was Chief of Technology Development and Vice President of Research at KAI Pharmaceuticals, Inc., where he led the discovery, engineering and early development of velcalcetide(TM).

Dr. Johnson previously served at Roche Bioscience as Department Head of Molecular & Cellular Biochemistry, Center for Biological Research.